A clinical evaluation committee assessment of recombinant human tissue factor pathway inhibitor (tifacogin) in patients with severe community-acquired pneumonia.

ABSTRACT:

Introduction

The purpose of this analysis was to determine the potential efficacy of recombinant human tissue factor pathway inhibitor (tifacogin) in a subpopulation of patients with community-acquired pneumonia (CAP) from a phase III study of severe sepsis.

Methods

A retrospective review of patients with suspected pneumonia was conducted by an independent clinical evaluation committee (CEC) blinded to treatment assignment. The CEC reanalyzed data from patients enrolled in an international multicenter clinical trial of sepsis who had a diagnosis of pneumonia as the probable source of sepsis. The primary efficacy measure was all-cause 28-day mortality.

Results

Of 847 patients identified on case report forms with a clinical diagnosis of pneumonia, 780 (92%) were confirm

SUBMITTER: Laterre PF 

PROVIDER: S-EPMC2689471 | biostudies-literature | 2009

REPOSITORIES: biostudies-literature